Cencora, Inc. filed a Form 8-K on November 4, 2026, disclosing a reorganization of its operating model and a new three-segment reporting structure that will take effect beginning in the first quarter of fiscal 2027.

Key Highlights

  • New structure: Cencora reorganized all business components within its U.S. Healthcare Solutions and International Healthcare Solutions reportable segments into a new framework effective in fiscal 2027.
  • Three reporting categories: The new structure consists of Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
  • Pharmaceutical Distribution and Services: According to the filing, this segment will consist of U.S. and international wholesale pharmaceutical distribution and related services supporting health systems, retail pharmacies, and alternate sites of care.
  • Specialty Pharmaceutical and Provider Services: The filing states this segment will include specialty distribution to physician practices, management services organizations, World Courier, third-party logistics services, Innomar, and strategic components of PharmaLex.
  • Other category: MWI Animal Health, Profarma, and certain other components of PharmaLex are grouped under Other, which the company disclosed is not considered a reportable segment and includes "businesses for which the Company is exploring strategic alternatives."
  • Supplemental historical data furnished: Exhibit 99.1 provides unaudited revised summary reportable segment information for each quarter of fiscal 2026 and 2025 and the fiscal years ended September 30, 2026 and 2025.

Cencora's Reorganized Reporting Model and What It Covers

Cencora, Inc. (NYSE:COR) filed a current report on November 4, 2026, under Item 7.01 (Regulation FD Disclosure), explaining a recently completed restructuring of its operating model. According to the filing, the restructuring was intended "to strengthen execution and improve visibility" and advance the company's growth priorities. The reorganization dissolves the previous U.S. Healthcare Solutions and International Healthcare Solutions reportable segment framework in favor of three new categories.

The filing describes Pharmaceutical Distribution and Services as the segment covering wholesale pharmaceutical distribution and related services, both domestically and internationally, for health systems, retail pharmacies, and alternate sites of care. The Specialty Pharmaceutical and Provider Services segment, as described in the filing, will encompass specialty distribution to physician practices, management services organizations, World Courier, third-party logistics services, Innomar, and strategic components of PharmaLex. The Other category, which the company stated is not a reportable segment, includes MWI Animal Health, Profarma, and remaining PharmaLex components, all described as businesses under strategic alternatives review.

To help investors analyze the transition, Cencora voluntarily furnished Exhibit 99.1, containing unaudited revised summary reportable segment information recast under the new structure for each quarter of fiscal 2026 and 2025, as well as full fiscal years ended September 30, 2026 and 2025. The filing notes the information is furnished, not filed, and is therefore not subject to Section 18 liabilities of the Securities Exchange Act of 1934. The report was signed by Eva C. Boratto, Executive Vice President and Chief Financial Officer.

What Was Disclosed

Cencora disclosed a completed restructuring of its operating model, the creation of three new reporting categories effective in fiscal 2027's first quarter, and voluntarily furnished historical segment data recast under the new structure for fiscal years 2025 and 2026.